GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » Inventory-to-Revenue

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Inventory-to-Revenue : 0.76 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sunshine Guojian Pharmaceutical (Shanghai) Co's Average Total Inventories for the quarter that ended in Mar. 2025 was ¥235 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's Revenue for the three months ended in Mar. 2025 was ¥311 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.76.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 declined from Dec. 2024 (0.85) to Dec. 2024 (0.76)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sunshine Guojian Pharmaceutical (Shanghai) Co's Days Inventory for the three months ended in Mar. 2025 was 286.04.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.32.


Sunshine Guojian Pharmaceutical (Shanghai) Co Inventory-to-Revenue Historical Data

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Guojian Pharmaceutical (Shanghai) Co Inventory-to-Revenue Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec12 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.23 0.27 0.21 0.18

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.62 0.57 0.85 0.76

Competitive Comparison of Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue falls into.


;
;

Sunshine Guojian Pharmaceutical (Shanghai) Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (A: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )
=( (194.959 + 229.598) / 2 ) / 1193.568
=212.2785 / 1193.568
=0.18

Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue (Q: Mar. 2025 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2024 ) + Total Inventories (Q: Mar. 2025 )) / count ) / Revenue (Q: Mar. 2025 )
=( (229.598 + 240.734) / 2 ) / 311.119
=235.166 / 311.119
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Guojian Pharmaceutical (Shanghai) Co  (SHSE:688336) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2025 )/Cost of Goods Sold (Q: Mar. 2025 )*Days in Period
=235.166/75.02*365 / 4
=286.04

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2025 ) / Average Total Inventories (Q: Mar. 2025 )
=75.02 / 235.166
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Guojian Pharmaceutical (Shanghai) Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
Executives
Weng Zhi Bing Core technical personnel
Huang Hao Min Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines